Drugs / hI-con1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01485588 | Dec 2010 → Mar 2012 | wet macular degeneration | Iconic Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02358889 | Feb 2015 → Sep 2016 | age-related macular degeneration, choroidal neovascularization | Iconic Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hI-CON1 | “A Phase 1 / 2 Trial to Investigate The Safety and Tolerability of Single and Repeated Doses of hI-CON1™ Following Administration by Intravitreal Injection in Subjects With...” NCT01485588 ↗ |
| Route | Intravitreal | “Following Administration by Intravitreal Injection” NCT01485588 ↗ |